As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…

With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the…

Singapore's Agency for Science, Technology and Research will work with Merck on potential ways to help reach into cells with macrocyclic peptides.

China and Japan were unexpected bright spots for Eli Lilly in the second quarter.

The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…

Two of the world’s largest generics makers are looking to lay their hands on the largest generics manufacturing plant in Latin America, sources tell Reuters,…

GlaxoSmithKline CEO Andrew Witty is sitting pretty. For the second straight quarter, his much-maligned growth strategy has come through for the drugmaker,…

In second-quarter results released Wednesday, GSK's vax group notched the highest growth of the company’s three major units as it inched toward £1 billion…

Bayer’s pharma lineup churned out growth for yet another quarter, racking up a 5.5% sales hike to €4.1 billion as the blood thinner Xarelto and vision med…